🚀 LIXTE Biotechnology Dives into Crypto!
Foresight News reports that Nasdaq-listed LIXTE Biotechnology has approved a bold new capital strategy. The board has greenlit allocating 25% of company funds into cryptocurrencies — starting with Bitcoin and potentially expanding to other digital assets based on market conditions.
